504257001 03/06/2017

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4303681

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
JANSSEN-CILAG, S.A.	08/01/2014

RECEIVING PARTY DATA

Name:	JANSSEN PHARMACEUTICA NV	
Street Address:	TURNHOUTSEWEG 30	
City:	BEERSE	
State/Country:	BELGIUM	
Postal Code:	B-2340	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15500600

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

JNJUSPATENT@CORUS.JNJ.COM Email:

Correspondent Name: JOSEPH SHIRTZ

Address Line 1: ONE JOHNSON AND JOHNSON PLAZA Address Line 4: NEW BRUNSWICK, NEW JERSEY 08933

ATTORNEY DOCKET NUMBER:	JAB6033USPCT	
NAME OF SUBMITTER:	SONNY NKANSA	
SIGNATURE:	/Sonny Nkansa/	
DATE SIGNED:	03/06/2017	

Total Attachments: 1

source=JAB6033_Gen_asg_cilag_to_inv#page1.tif

PATENT REEL: 041471 FRAME: 0593

504257001

General Assignment

WHEREAS, Janssen-Cilag, S.A., having its place of business at EDIFICIO JOHNSON & JOHNSON, Paseo de las Doce Estrellas, 5-7, 5° planta, Campo de las Naciones, 28042 Madrid, Spain (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

6,7-DIHYDROPYRAZOLO[1,5-8]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE
ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

for which on the 1st day of August 2014, European Patent Application no. EP 14179598.9 was filed at the European Patent Office.

WHEREAS, Janesen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter referred to as "Assignee") is desirous of acquiring Assignor's entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that In view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 1st day of August 2014,

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen-Cilag, S.A.

Frank Daelemans Authorized Signatory

Janssen-Cilag, S.A.

For Janssen Pharmaceutica NV

Luc Quaghebeur Authorized Signatory

Janssen Pharmaceutica NV

PATENT REEL: 041471 FRAME: 0594

RECORDED: 03/06/2017